Institution Directory

Clinical trials at MD Anderson Cancer Center

Sites in Houston, TX

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2398

Shown on this page

Current sort

Live official records

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions: OrcaGraft (Orca-Q); Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 12 Years to 78 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Duarte, California • Sacramento, California • Stanford, California + 9 more

Conditions: Breast Inflammatory Carcinoma
Interventions: Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration; Procedure · Drug · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 214
States / cities: Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more

Conditions: Solid Tumours
Interventions: Brigimadlin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 13
States / cities: Beverly Hills, California • Santa Monica, California • New Haven, Connecticut + 10 more

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Durvalumab, Echocardiography Test, Magnetic Resonance Imaging, Olaparib, X-Ray Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 17
States / cities: Buena Park, California • Los Angeles, California • Newport Beach, California + 10 more

Conditions: Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter, Urothelial Carcinoma Ureter Recurrent, Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma of the Renal Pelvis and Ureter, Carcinoma, Transitional Cell, Transitional Cell Carcinoma of Renal Pelvis
Interventions: Jelmyto (mitomycin) for pyelocalyceal solution; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 22
States / cities: Santa Monica, California • Gainesville, Florida • Miami, Florida + 17 more

Conditions: Relapsed or Refractory T Cell Lymphoma
Interventions: ONO-4685; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 17 more

Conditions: Neoplasms
Interventions: RO7673396; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Duarte, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Prostatic Neoplasms, Castration-Resistant
Interventions: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg, Prednisone 5 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 19
States / cities: Tucson, Arizona • Denver, Colorado • Jacksonville, Florida + 15 more

Conditions: Skin Kaposi Sarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pomalidomide, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: La Jolla, California • Miami, Florida • Chicago, Illinois + 9 more

Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions: IDE892, IDE397; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Conditions: Advanced Solid Tumor
Interventions: BG-75098, BGB-43395, Fulvestrant; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Birmingham, Alabama • Duarte, California • New Haven, Connecticut + 4 more

Conditions: Advanced Solid Tumor, Solid Tumor
Interventions: BGB-26808, Tislelizumab, Chemotherapy; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 337 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • New Haven, Connecticut + 6 more

About this MD Anderson Cancer Center institution page

What this page lists: ClinicalTrials.gov records that list MD Anderson Cancer Center in Houston, TX as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at MD Anderson Cancer Center

Filter and sort this campus

Live official records

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Pomalidomide Treatment in Patients With Kaposi Sarcoma

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

About this MD Anderson Cancer Center institution page